DCOY - Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding
DCOY - Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Decoy Therapeutics explores pan-filovirus program via FDA Animal Rule
Decoy Therapeutics said its next-generation D-MAVs showed potent in-vitro activity against Ebola Zaire and Marburg, and that it is exploring a pan-filovirus program using the FDA Animal Rule pathway and non-dilutive funding, targeting potential FDA Priority Review Voucher eligibility.